Daniel A. Vallera
Section on Molecular Cancer Therapeutics
Department of Therapeutic Radiology-Radiation Oncology
University of Minnesota Cancer Center
Minneapolis 55455
USA
Name/email consistency: high
- Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Vallera, D.A., Elson, M., Brechbiel, M.W., Dusenbery, K.E., Burns, L.J., Jaszcz, W.B., Ramsay, N.K., Panoskaltsis-Mortar, A., Kuroki, D.W., Wagner, J.E., Vitetta, E.S., Kersey, J.H. Cancer Biother. Radiopharm. (2004)
- Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. Vallera, D.A., Li, C., Jin, N., Panoskaltsis-Mortari, A., Hall, W.A. J. Natl. Cancer Inst. (2002)
- Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene. Vallera, D.A., Jin, N., Baldrica, J.M., Panoskaltsis-Mortari, A., Chen, S.Y., Blazar, B.R. Cancer Res. (2000)
- Molecular modification of a recombinant anti-CD3epsilon-directed immunotoxin by inducing terminal cysteine bridging enhances anti-GVHD efficacy and reduces organ toxicity in a lethal murine model. Vallera, D.A., Kuroki, D.W., Panoskaltsis-Mortari, A., Buchsbaum, D.J., Rogers, B.E., Blazar, B.R. Blood (2000)